论文部分内容阅读
目的:应用双通道技术联合眼表综合分析仪评价重组人表皮生长因子(rhEGF)衍生物滴眼液治疗中度干眼伴浅层点状角膜病变(SPK)的效果,并评判治疗前后视觉质量的变化。方法:选择中度干眼伴SPK患者48例(96眼),随机分为治疗组和对照组。治疗组使用人工泪液联合rhEGF衍生物滴眼液治疗,对照组单用人工泪液治疗,记录治疗前、治疗后(3±1)d、(7±1)d、(14±2)d、(28±1)d角膜荧光染色(FL)消失率、眼表指数评分(OSDI)调查问卷、泪液分泌实验(Schimer-ⅠTest,SⅠT)、眼表综合分析仪相关参数(结膜充血程度评分、泪河高度、泪膜破裂时间(BUT))、双通道视觉质量分析系统(OQAS)相关参数[调制传递函数(MTF)截止频率(MTF cut off)、斯特列尔比(SR)、客观散射指数(OSI)均值及标准差]。结果:治疗前,治疗组与对照组各指标差异均无统计学意义(P>0.05);治疗后(3±1)d、(7±1)d、(14±2)d、(28±1)d两组各指标差异均有明显统计学意义(P<0.05)。结论:rhEGF衍生物滴眼液联合人工泪液能有效改善中度干眼伴SPK的临床症状及体征,并能显著提高患者的视觉质量,效果优于单用人工泪液;眼表综合分析仪及OQAS提供客观量化的指标,可辅助医生对患者进行个性化治疗。
Objective: Combined dual channel ocular Analyzer Evaluation of recombinant human epidermal growth factor (rhEGF) derivative with dry eye drops to treat moderate effect superficial punctate keratopathy (SPK), and the visual quality evaluation before and after treatment The change. Methods: Forty-eight patients (96 eyes) with moderate dry eye accompanied by SPK were randomly divided into treatment group and control group. The patients in the treatment group were treated with artificial tears combined with rhEGF derivative eye drops. The control group was treated with artificial tears only. Before treatment, the patients were treated with (3 ± 1) d, (7 ± 1) d, (14 ± 2) days, 28 ± 1) d corneal fluorescein staining (FL) disappearance rate, ocular index score (in OSDI) questionnaire, Schirmer test (Schimer-ⅰTest, SⅠT), ocular analyzer parameters (conjunctival hyperemia score, tear meniscus (BUT), OQAS-related parameters [MTF cutoff, SR, objective scattering index ( OSI) mean and standard deviation]. Results: Before treatment, there was no significant difference in each index between treatment group and control group (P> 0.05) 1) d, the differences between the two groups were statistically significant (P <0.05). Conclusion: rhEGF derivatives combined eyedrops, artificial tears can improve with moderate dry eye SPK clinical symptoms and signs, and can significantly improve the visual quality of the patient, better than artificial tears alone; ocular Analyzer and OQAS Provide objective and quantitative indicators to assist doctors in personalized treatment of patients.